---
title: "Pharvaris N.V. (PHVS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PHVS.US.md"
symbol: "PHVS.US"
name: "Pharvaris N.V."
industry: "Pharmaceuticals"
datetime: "2026-05-20T10:13:37.324Z"
locales:
  - [en](https://longbridge.com/en/quote/PHVS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PHVS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PHVS.US.md)
---

# Pharvaris N.V. (PHVS.US)

## Company Overview

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [arvaris.com](https://arvaris.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.19 | 189 | - | - | - |
| PB | 7.41 | 168 | 7.41 | 4.97 | 4.45 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 69% |
| Overweight | 3 | 23% |
| Hold | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 28.95 |
| Highest Target | 75.08 |
| Lowest Target | 30.11 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PHVS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PHVS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PHVS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PHVS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**